A detailed history of Captrust Financial Advisors transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Captrust Financial Advisors holds 9,756 shares of NBIX stock, worth $1.24 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
9,756
Previous 8,158 19.59%
Holding current value
$1.24 Million
Previous $1.13 Million 19.38%
% of portfolio
0.0%
Previous 0.0%

Shares

19 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$130.86 - $143.19 $209,114 - $228,817
1,598 Added 19.59%
9,756 $1.34 Million
Q1 2024

May 15, 2024

SELL
$130.4 - $143.74 $478,959 - $527,957
-3,673 Reduced 31.05%
8,158 $1.13 Million
Q4 2023

Feb 14, 2024

BUY
$106.07 - $132.76 $886,214 - $1.11 Million
8,355 Added 240.36%
11,831 $1.56 Million
Q3 2023

Nov 14, 2023

BUY
$94.02 - $117.1 $46,351 - $57,730
493 Added 16.53%
3,476 $391,000
Q2 2023

Aug 14, 2023

BUY
$89.53 - $104.87 $8,953 - $10,487
100 Added 3.47%
2,983 $281,000
Q1 2023

May 15, 2023

SELL
$94.11 - $123.02 $5,928 - $7,750
-63 Reduced 2.14%
2,883 $291,000
Q4 2022

Feb 15, 2023

BUY
$106.72 - $127.06 $108,534 - $129,220
1,017 Added 52.72%
2,946 $351,000
Q3 2022

Nov 16, 2022

BUY
$92.03 - $107.81 $24,387 - $28,569
265 Added 15.93%
1,929 $205,000
Q2 2022

Aug 23, 2022

SELL
$75.79 - $100.07 $12,429 - $16,411
-164 Reduced 8.97%
1,664 $162,000
Q2 2022

Aug 16, 2022

BUY
$75.79 - $100.07 $32,892 - $43,430
434 Added 31.13%
1,828 $178,000
Q1 2022

May 16, 2022

SELL
$72.45 - $94.81 $7,607 - $9,955
-105 Reduced 7.0%
1,394 $131,000
Q4 2021

Feb 14, 2022

BUY
$79.65 - $106.22 $18,478 - $24,643
232 Added 18.31%
1,499 $128,000
Q3 2021

Nov 16, 2021

BUY
$86.18 - $99.03 $2,671 - $3,069
31 Added 2.51%
1,267 $122,000
Q2 2021

Aug 16, 2021

BUY
$89.43 - $102.27 $18,333 - $20,965
205 Added 19.88%
1,236 $120,000
Q1 2021

May 17, 2021

BUY
$87.57 - $119.4 $90,284 - $123,101
1,031 New
1,031 $100,000
Q4 2019

Feb 14, 2020

SELL
$86.8 - $118.57 $9,287 - $12,686
-107 Closed
0 $0
Q1 2019

May 15, 2019

BUY
$69.31 - $91.53 $7,416 - $9,793
107 New
107 $9,000
Q4 2018

Feb 13, 2019

SELL
$68.32 - $124.36 $10,521 - $19,151
-154 Closed
0 $0
Q3 2018

Nov 15, 2018

BUY
$98.88 - $125.85 $15,227 - $19,380
154 New
154 $19,000

Others Institutions Holding NBIX

About NEUROCRINE BIOSCIENCES INC


  • Ticker NBIX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 95,639,296
  • Market Cap $12.1B
  • Description
  • Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...
More about NBIX
Track This Portfolio

Track Captrust Financial Advisors Portfolio

Follow Captrust Financial Advisors and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Captrust Financial Advisors, based on Form 13F filings with the SEC.

News

Stay updated on Captrust Financial Advisors with notifications on news.